Rekha Hemrajani has served on our Board since June 2021. Previously, Ms. Hemrajani served as chief executive officer and a director of Jiya Acquisition Corporation, a special purpose acquisition company, as president and chief executive officer and a director of Aravive, Inc., a clinical-stage biotechnology company, as the chief operating officer and chief financial officer of Arcus Biosciences, a biotechnology company, as chief operating officer of FLX Bio, Inc. (now RAPT Therapeutics, Inc.), a biotechnology company, as chief financial officer and senior vice president of business and financial operations at 3-V Biosciences, Inc. (now Sagimet Biosciences, Inc.), a biotechnology company.
Ms. Hemrajani currently serves as a director of the publicly held company ALX Oncology Holdings, Inc., as well as BioAge Labs, a privately held company. She holds a BS in economics and computer science from the University of Michigan and an MBA from the Kellogg Graduate School of Management at Northwestern University.
Our Board believes Ms. Hemrajani is qualified to serve as a director due to her executive and financial experience at multiple companies in the biopharmaceutical and biotechnology industries.
What is Rekha Hemrajani's net worth?
The estimated net worth of Rekha Hemrajani is at least $52.26 thousand as of June 25th, 2025. Ms. Hemrajani owns 39,893 shares of MaxCyte stock worth more than $52,260 as of August 27th. This net worth estimate does not reflect any other investments that Ms. Hemrajani may own. Learn More about Rekha Hemrajani's net worth.
How do I contact Rekha Hemrajani?
Has Rekha Hemrajani been buying or selling shares of MaxCyte?
Rekha Hemrajani has not been actively trading shares of MaxCyte during the last ninety days. Most recently, Rekha Hemrajani sold 10,684 shares of the business's stock in a transaction on Wednesday, June 25th. The shares were sold at an average price of $2.09, for a transaction totalling $22,329.56. Following the completion of the sale, the director now directly owns 39,893 shares of the company's stock, valued at $83,376.37. Learn More on Rekha Hemrajani's trading history.
Who are MaxCyte's active insiders?
Are insiders buying or selling shares of MaxCyte?
In the last year, insiders at the sold shares 1 times. They sold a total of 10,142 shares worth more than $8,215.02. The most recent insider tranaction occured on March, 17th when CFO Douglas J Swirsky sold 10,142 shares worth more than $8,215.02. Insiders at MaxCyte own 4.1% of the company.
Learn More about insider trades at MaxCyte. Information on this page was last updated on 3/17/2026.
